Leukemia

Questions discussed in this category

For CLL patients with high-risk cytogenetics on ibrutinib who develop a cardiac event such as an MI, would you continue ibrutinib?

Would you continue ibrutinib even if they are placed on anti-platelet therapy such as clopidogrel or ticagrelor? When do you switch to an altern...

5 Answers available

What are the treatment options for relapsed T-ALL in a patient who was nonadherent with AALL and hyper-CVAD regimens?

Is there a role for nelarabine and venetoclax in this setting?

1 Answer available

What is your approach to treatment of relapsed, high-risk MDS with TP53 mutation in a patient that is not considered a transplant candidate?

1 Answer available

How do you incorporate blinatumomab into therapy for a pediatric or AYA patient with isolated CNS relapse of B-ALL, if at all?

1 Answer available

Do complex cytogenetics have any therapeutic or prognostic relevance in CLL?

Patient in their 60s with TP53 mutation by NGS, treated 12 years ago with FCR, then at first relapse 2 years ago started ibrutinib. Bone marrow biopsy...

1 Answer available

Would you re-challenge a CLL patient, who had good response to Zanubrutinib but contracted cryptococcal pneumonia, with another BTK inhibitor?

1 Answer available

What is the consensus on giving Pemivibart for Pre-Exposure COVID prophylaxis in immunocompromised patients?

1 Answer available

What is your approach to re-challenging BTK inhibitors for a patient who has had intolerance to several different agents?

Patient developed atrial fibrillation on Ibrutinib, severe fatigue and intolerance to Zanubrutinib and a maculopapular rash (grade 2) on Acalabrutinib

1 Answer available

In patients with HTLV-1 associated acute T-cell leukemia, is there any clear benefit of adding antivirals?

If yes, would you go with Zidovudine monotherapy versus combining with interferon-alpha? And what would be the preferred dose and duration?

1 Answer available

Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?

The patient presented with a numb chin, more to the right of his face; an MRI did report mandibular nerve opacity, which is non-specific per neuro-rad...

1 Answer available

How do you address logistic barriers related to blinatumomab when treating relapsed B-ALL?

For example, if patients are unable to receive continuous infusion from home health agencies, or if prolonged hospitalization is cost-prohibitive.&nbs...

2 Answers available

How has your approach to utilizing MRD-guided therapy in previously untreated CLL changed since the FLAIR trial, particularly in choosing between continuous versus time-limited treatment?

2 Answers available

How do you manage severe hypertriglyceridemia in the adolescent & young adult population receiving chemotherapy for ALL, in the absence of complications related to hypertriglyceridemia?

1 Answer available

What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?

Have you changed your practice given BMT-CTN 1506/Morpho results? Would you utilize maintenance therapy in patients who achieve MRD- remission?

1 Answer available

Does the presence of asparaginase antibodies on Granger Genetics testing indicate need to switch asparaginase formulations?

1 Answer available

In what situations do you use G-CSF for patients undergoing allogeneic HSCT to facilitate engraftment?

How does graft source, conditioning regimen, and indication for transplant affect your decision regarding G-CSF?

2 Answers available

How would you manage a patient with CML in chronic phase with a significant cardiac history, such as heart failure with reduced ejection fraction or arrhythmia?

Is there a specific tyrosine kinase inhibitor that you would prefer to use?

1 Answer available

For AML patients, when do you stop antiinfective agents?

At the time of count recovery or do you continue it throughout induction and consolidation?

1 Answer available

Would concurrent CRLF2/IgH rearrangement affect your treatment recommendations for an adult patient with Ph+ p190 high risk (Age>35, WBC >30) B-cell ALL that was started on induction therapy with ponatinib + blinatumomab?

Comorbidities: morbid obesity, diabetes, hypertension

1 Answer available

How would you treat an LGL leukemia patient who has been refractory to treatments with cyclosporine, MTX, and cyclophosphamide?

The patient also has transfusion-dependent anemia secondary to the LGL leukemia.

1 Answer available

Do you prefer to use 7+3 or CPX-351 as standard induction therapy in younger patients with AML-MRC or t-AML?

Given CPX-351 was given to elderly patients ages 60-75 with a lower dose (60 mg/m2) Daunorubicin, can one generalize from this study to younger adults...

1 Answer available

Would you treat with AZA + venetoclax to achieve CR2 before proceeding to allogeneic stem cell transplant in a young, fit patient with favorable risk AML who relapsed within a year after 7+3 and HIDAC consolidation?

NGS results are pending

1 Answer available

How would you manage an elderly patient with mild pancytopenia who refuses bone marrow biopsy and whose flow cytometry is suggestive of CMML/MDS?

2 Answers available

Is it possible to give Inotuzumab ozogamicin in the front line setting for an older patient with Ph- Pre-B-ALL?

1 Answer available

How should one approach an incidentally found T-cell gene arrangement?

Work-up was performed for isolated anemia which resolved to >11 g/dl after the reversible cause was treated.

1 Answer available

For a pediatric patient with B-ALL who requires surgery during maintenance, what therapy modifications do you recommend to allow for optimal healing and minimal treatment disruption?

For a pediatric patient with B-ALL who needs elective surgery during maintenance, what are potential treatment options during the month recommended fo...

1 Answer available

When would you use acalabrutinib in combination with obinutuzumab vs acalabrutinib alone in upfront CLL treatment?

1 Answer available

What are your top takeaways in Hematologic Malignancies from ASCO 2023?

8 Answers available

How do you manage severe cytarabine syndrome in AML patients, manifesting as severe hypotension, fevers, rash, and myalgias?

Do you re-challenge them? If so, what pre-medications do you give? Do you dose reduce the cytarabine? Or do you switch another regimen?

1 Answer available

What's the role of ibrutinib and venetoclax in CLL in light of data emerging from ASH 2022?

1 Answer available

Do you check asparaginase levels for all patients receiving receiving E. coli-derived products, or only in certain clinical situations?

1 Answer available

Would you consider TKI discontinuation in a patient who has negative BCR transcripts on Bosutinib?

Data exists for imatinib Dasatinib and nolotinib

1 Answer available

Would you use a matched sibling donor with a germline heterozygous BRCA1 mutation for stem cell transplant?

Presuming there are no matched unrelated donors.

1 Answer available

Is a CLL FISH panel sufficient to aid in treatment decisions in CLL or is p53 sequence analysis also needed?

1 Answer available

Do you consider resuming Venetoclax for patients with CLL upon progression/recurrence, in whom Venetoclax/Rituximab achieved CR and Venetoclax was previously well tolerated but stopped after completing 2 years of therapy?

1 Answer available

For T cell ALL treated in CR (without transplant), how often do you do BM biopsies as part of surveillance, and for how long?

What would you want community oncologists to know when following these patients? Are there any other special issues to follow especially in AYA?

1 Answer available

How do you approach a patient with CP-CML who has a history of inadequate response and severe myelotoxicity to multiple TKIs such as imatinib, nilotinib and dasatinib?

The patient has also acquired mutations in BCR-ABL, namely p.Met244Val, (c.730A>G); 3.7%, which may confer resistance, and p.Phe359Cys, (c.1076T>...

1 Answer available

Would you recommend adding a TKI to a pediatric regimen for a AYA B-ALL patient with IKZF1 mutation?

1 Answer available

Would it be reasonable to offer a patient with CLL a treatment break from acalabrutinib or any BTK inihibitor after a period of time, assuming good response?

It is understood that the trial's experience was to keep on treatment indefinitely until progression or unacceptable toxicity. We are asking about rea...

1 Answer available

Would you ever consider using ibrutinib in CLL patients who have received first line acalabrutinib and then progressed?

3 Answers available

In a patient with HR B ALL and severe pancreatitis due to peg-asparaginase, how do you assess the impact of peg discontinuation on risk of relapse?

For patients not on study, would you consider replacing missed doses of peg with a non-asparaginase based chemotherapy?

2 Answers available

Do you switch from imatinib to another TKI in patients with chronic phase CML who develop renal insufficiency?

There are conflicting reports whether it contributes to renal insufficiency. If you do switch, what is your preferred TKI in this scenario?

2 Answers available

Based on the ASC4MORE trial, would you add asciminib to imatinib if patients do not achieve deep molecular remission at 1-year?

2 Answers available

How long do you continue treatment with imatinib in a patient with chronic eosinophilic leukemia who achieves remission?

If indefinite treatment is recommended, is there an optimal maintenance dose?

1 Answer available

What is the treatment approach if an AML patient receiving azacitidine/venetoclax is later found to have FLT3 and IDH2 mutations?

1 Answer available

What is your first line strategy for TP53 mutant AML?

1 Answer available

What is your preferred frontline treatment for CLL in young patients < 50 years old?

2 Answers available

How would you treat a patient with chronic phase CML who could not tolerate nilotinib due to G4 thrombocytopenia despite sequential dose reductions?

1 Answer available

Do you do prophylactic LP/IT chemotherapy in high risk APML prior to starting consolidation?

1 Answer available

When and how do we do cytoreduction in CLL?

1 Answer available

What is your approach to CMML-MDS in an older patient with low risk disease who is becoming transfusion dependent?

Would you use a trial of dexamethasone for a patient with thrombocytopenia?

1 Answer available

What is the appropriate management of arthralgias associated with bosutinib?

1 Answer available

Which patients with acute promyelocytic leukemia do you consider maintenance after completing consolidation?

1 Answer available

How do you utilize p53 NGS testing in your treatment planning for patients with CLL?

What VAF burden would be considered significant prognostically or for treatment decisions?

1 Answer available

What is your preferred up-front treatment for transplant-eligible patients with primary (de novo) plasma cell leukemia?

2 Answers available

What is the treatment of choice for mixed phenotype ALL?

What are the differences in approach to B lymphoid/myeloid and T lymphoid/myeloid MPAL?

1 Answer available

For a patient who has core binding factor AML but also a small FLT3-ITD mutation detected, do you proceed with allo transplant or only HiDAC consolidation after achieving CR from induction chemotherapy?

1 Answer available

What is the role of PD-1 inhibitors in relapsed B-cell ALL?

What is the role of PD-1 inhibitors after CAR-T infusion, either as maintenance therapy or in the setting of relapsed disease?

1 Answer available

Would you continue venetoclax indefinitely/until disease progression in patients treated with upfront venetoclax for TP53 mutated CLL?

2 Answers available

What are your recommendations for a male patient who was recently started on imatinib and wants to conceive?

4 Answers available

What is your institutional approach to a restrictive “neutropenic diet”?

3 Answers available

What is the benefit of cytoreduction with Hydroxyurea for patients with newly diagnosed chronic phase CML with a WBC count >100 prior to the initiation of a TKI?

1 Answer available

How would you manage a pediatric patient with hypodiploid acute lymphoblastic leukemia?

2 Answers available

How do you choose which BTK inhibitor to use in NHL?

Does the safety profile impact your choice significantly? Does your first choice vary by disease histology?

1 Answer available

Which, if any, young/fit intermediate-risk AML patients would you not offer allogeneic transplant to in MRD- CR1?

1 Answer available

How does the presence of concurrent infections or wound issues affect your choice and timing of induction in patients with AML or MDS with excess blasts?

1 Answer available

In patients with CML on imatinib and newly diagnosed breast cancer now requiring radiation therapy, should we hold imatinib?

The said patient has been on Imatinib for 2.5 years and is In MMR. Last rt-PCR was 0.04.

3 Answers available

When would you consider additional testing for NUDT15 and other polymorphisms related to 6-MP/6-TG metabolism, if not guided by a study protocol?

2 Answers available

Would you include midostaurin in induction and consolidation for patients with good-risk AML w/ NPM1 mutation and FLT3-ITD (<0.5)?

1 Answer available

Is there any benefit to transplant patients with Ph+ ALL who have achieved MRD-negativity?

1 Answer available

For patients receiving outpatient venetoclax/azacitidine who develop profound neutropenia with ANC <200, do you admit for monitoring during the nadir in the absence of fever?

If not, what instructions do you give to patients regarding checking temperature at home/return precautions?

2 Answers available

How would you approach the treatment of cytopenia related to NK cell LGL leukemia?

1 Answer available

When would you opt for a chemotherapy free approach in the first line treatment for hairy cell leukemia?

What would you consider as contra-indications to Cladribine?

1 Answer available

How would you treat a pediatric or AYA patient with Ph-like ALL with induction failure?

1 Answer available

How should one manage a patient with leukocytosis and borderline detectable BCR-ABL without other clinical features of CML such as basophilia or splenomegaly?

e.g. IS < 0.002% by qPCR

1 Answer available

How do you approach patients with underlying psychiatric disorders who refuse CML treatment due to not believing their diagnosis?

1 Answer available

How do you approach conversations regarding discontinuation of transfusions in patients with advanced hematologic malignancies who are otherwise appropriate for hospice?

Are there other supportive care interventions that would otherwise be covered by hospice?

1 Answer available

Do you routinely offer fungal prophylaxis for patients on BTK inhibitors?

Can experts comment on fungal pneumonia risk with individual BTK inhibitors as seen in ELEVATE-RR and whether this impacts their management decisions?

3 Answers available

What is your approach to CLL in patients with atrial fibrillation and/or on anticoagulation?

Do you feel comfortable with BTK inhibitors in these patients? In ELEVATE-RR patients on a/c were excluded, and rate of atrial fibrillation in the ac...

3 Answers available

For frail patients with cardiac co-morbidities and relapsed CLL with high cytogenetic risk, what are some considerations for using continuous acalabrutinib over fixed duration therapies such as venetoclax/rituximab?

2 Answers available

What regimen would you offer a young patient with T-cell ALL who recurred a short time after allo-transplant and was initially treated with CALGB10403?

Especially with the current drug shortage of nelarabine.

2 Answers available

Would you start TKI therapy in a patient with new diagnosis of T-ALL without BCR-ABL gene rearrangement on FISH but found to have very low level p190 transcript on RT-PCR?

1 Answer available

How would you manage a CLL patient who experienced severe infusion reactions with rituximab and has exhausted all other options?

Is it safe to challenge with other CD20 monoclonal antibodies such as obinutuzumab?

1 Answer available

What regimen would you recommend for a younger, fit, transplant eligible patient with relapsed IDH1 positive AML?

1 Answer available

What is your starting dose of ponatinib for CML?

1 Answer available

What dose of PEG-asparaginase do you recommend for teens with high BMI treated on a pediatric ALL regimen?

Would you plan straight pediatric dosing using 2500 Units/m2 or a cap of 3750 Units as used in some adult ALL regimens due to excess liver/pancreas to...

2 Answers available

Would you consider allogeneic stem cell transplant for a newly diagnosed patient with favorable risk AML who had residual disease after initial therapy that included the need for re-induction?

1 Answer available

Is there data to support holding the 5th cycle of intensification for an AML patient with good prognosis and a history of significant infections and/or prolonged count recovery?

1 Answer available

What gemtuzumab regimen and schedule (with standard 7 plus 3) would you use for a newly diagnosed AML patient with favorable genetics?

1 Answer available

For a relapsed AML patient who has previously received 7+3 followed by HIDAC consolidation, how do you choose between FLAG-IDA or MEC re-induction?

1 Answer available

Under what circumstances would you consider outpatient induction for AML?

1 Answer available

Would you consider adding midostaurin to azacitadine in elderly patients with newly diagnosed AML with FLT3-ITD mutations in the frontline setting?

1 Answer available

How do you approach therapy for a fit adult with relapsed AML with CNS involvement after allogeneic stem cell transplantation?

Is Ommaya placement with CNS-directed therapy preferred to intrathecal or cranial irradiation? How do you interweave this therapy with systemic therap...

2 Answers available

Would you recommend stem cell transplant or gene therapy for a patient with CML and sickle cell disease currently on imatinib with worsening anemia?

1 Answer available

How do you decide between CPX-351 and HMA + Venetoclax in treating transplant eligible AML-MRC?

1 Answer available

Is a patient with secondary myeloid sarcoma a candidate for hematopoietic stem cell transplant?

2 Answers available

How would you approach a patient presenting with pancytopenia and splenomegaly whose bone marrow biopsy is morphologically normal but has a positive Philadelphia chromosome in bone marrow as well as peripheral blood?

2 Answers available

Would you add chemotherapy to a TKI in treating an elderly patient with de novo CML blast crisis?

1 Answer available

How do you decide between blinatumomab or traditional chemotherapy in combination with TKI for upfront treatment of adult patients with Ph + ALL?

1 Answer available

What would be your choice of therapy in a fit patient with relapsed CLL previously treated with bendamustine and rituximab who does not want BTK inhibitor therapy?

Relapsed disease occurred 3.5 years after initial treatment

2 Answers available

How would you manage CML first-line second generation TKI with a best response of MMR 4, but now with a loss of MMR with more than one log response loss but still in complete cytogenetic remission and mutation panel negative?

1 Answer available

What would be your choice for re-induction in a young patient with FLT3+ refractory AML after 7+3 induction therapy with no FLT3 mutation on the day 14 marrow?

1 Answer available

How would you treat a de novo CLL with WBC of 1,000,000 and no overt signs of leukostasis?

1 Answer available

How do you factor time from past cytotoxic chemotherapy exposure into diagnosing therapy-related AML?

Many patients have had prior chemotherapy exposure with newly diagnosed AML that may not have classic therapy-related cytogenetics. How do you a...

1 Answer available

Would you consider holding treatment with hypomethylating agents and venetoclax in elderly patients diagnosed with AML who achieve CR and are MRD negative?

1 Answer available

What is you approach for first line treatment in an elderly patient >85 years of age with good PS and a hairy cell leukemia variant?

2 Answers available

How do you choose chemotherapy for a pediatric patient with mixed-phenotype acute leukemia?

Patient's leukemia has both T and Myeloid lineages

1 Answer available

What maintenance treatment would you recommend for Ph positive ALL following Hyper-CVAD, transplant eligible or ineligible?

1 Answer available

Do you offer enasidenib with azacitadine in AML with an IDH2 mutation for patients ineligible for intensive induction chemotherapy?

Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?

2 Answers available

Are there any special considerations for treating CML in the very elderly, greater than 85 years old?

1 Answer available

What frontline therapy would you offer for a patient who is elderly or unfit for standard induction therapy with both IDH-2 and FLT-3 ITD mutations?

1 Answer available

How would you approach treatment in an otherwise young, fit patient with transformed AML currently in remission with a plan for transplant and was found to have an invasive fungal infection not amenable to resection upon recovery from induction?

Would you consider “bridging” therapy with something like an HMA?

1 Answer available

How do you adjust the dose of Ibrutinib in hepatic dysfunction, particularly if disease related?

1 Answer available

Would you consider adding Enasidinib to frontline combination therapy with HMA and Venetoclax in a patient with newly diagnosed AML with IDH2 mutation that is >75 or unfit for standard induction therapy?

1 Answer available

During induction therapy for acute leukemia, when do you decide to discontinue the antimicrobial prophylaxis?

Is it at neutrophil recovery, at documentation of CR on bone marrow biopsy, or is there a different point in time?

1 Answer available

What are the options of induction treatment of young AML patients who are on CRRT, continuous renal replacement therapy ?

1 Answer available

How do you approach the treatment of patients with an e14a3 (b3a3) BCR-ABL fusion in chronic phase CML?

1 Answer available

For pre-menopausal female patients who present with acute leukemia in need of urgent anti-neoplastic therapy, what is your preferred approach in effort to preserve fertility?

Does acute leukemia sub-type affect your decision?

1 Answer available

When during ALL induction therapy are you checking for MRD?

1 Answer available

What's your preferred management for a newly diagnosed chronic phase CML with concurrent thrombocytopenia?

1 Answer available

How long after discontinuation of TKI (for complete remission) would you feel it is safe for a patient with CML to consider pregnancy?

1 Answer available

How do you diagnose acute leukemia-mixed phenotype?

What is your preferred treatment?

1 Answer available

Do you ever discontinue ibrutinib in patients with CLL who have a good response?

For instance, would you discontinue when there is resolution of adenopathy and normalization of counts? If so, do you overlap ibrutinib with other the...

1 Answer available

What factors do you consider when choosing between a 1st and 2nd generation TKI in a newly diagnosed CML patient?

1 Answer available

How do you manage persistent cytopenias in patients with AML who achieve a complete remission with incomplete count recovery after venetoclax and HMA?

2 Answers available

Do you prefer hyper-CVAD or the CALGB 9111 protocol for high intensity remission induction treatment in Ph-negative ALL patients?

The NCCN recommends both regimens.

1 Answer available

Do you offer fertility preservation to patients prior to CAR-T therapy?

Do you limit it to post-pubertal patients? Do you offer it only if they will proceed with bone marrow transplantation after CAR-T?

1 Answer available

What is your TKI preference in patients with chronic phase CML on hemodialysis?

1 Answer available

Do you include gemtuzumab ozogamicin for any of your newly diagnosed AML patients who are candidates for 7+3 induction chemotherapy?

Or do you consider addition of this agent in the re-induction setting for refractory disease?

1 Answer available

What is your recommendations for vaccines to prevent shingles in CLL patients?

1 Answer available

Why do we immediately perform CNS staging with a LP at diagnosis of ALL when the risk of seeding is highest with a high lymphoblast count?

1 Answer available

How would you manage a patient with minimal residual disease (<1% of CD25 positive cells) six months after completing therapy with 2-CDA for Hairy Cell Leukemia?

2 Answers available

Would you offer next-line systemic therapy to a patient with LGL leukemia with chronic severe neutropenia, who has had treatment failure with methotrexate, cyclophosphamide, cyclosporine, and danazol?

If the patient has not experienced significant infectious complications? If so, what agent?

2 Answers available

Do you ever start with lower than standard doses of TKIs when initiating treatment for chronic phase CML?

For instance, do you ever start with dasatinib 50 mg daily? Are there any titration schedules that you follow?

1 Answer available

Can we ever observe newly diagnosed chronic phase CML patients and not immediately start them on therapy?

if so, are there specific cytogenetic, molecular, clinical, or hematologic factors that you take into consideration?

2 Answers available

How would you manage a CML patient with a T315I mutation that developed severe abdominal pain requiring hospitalization after starting ponatinib 45 mg?

Thrombosis was ruled out and no etiology was found. Would you start ponatinib back at a lower dose, transition to omacetaxine or begin transplan...

1 Answer available

For patients who have exceptionally long responses to HMA with high risk MDS or AML and not candidate for more aggressive therapy/transplant, do you consider treatment holidays or spacing out doses into longer intervals?

3 Answers available

For a patient with relapsed FLT3 positive AML on HMA and venetoclax, is there ever a role for the addition of midostaurin to the treatment regimen to improve response rate?

1 Answer available

With the recent FDA approvals of Venetoclax and Glasdegib in AML, is one generally preferred over the other for elderly and/or unfit patients in combination with a hypomethylating agent/low-dose cytarabine?

1 Answer available

In a newly diagnosed elderly patient with AML who harbors an IDH1 mutation, would you treat with upfront with ivosidenib or would you proceed with venetoclax and HMA as your first line treatment?

1 Answer available

Do you use absolute WBC count or doubling time to determine whether to start treatment for early stage CLL?

Would this affect your decision regardless of the stage and symptoms?

2 Answers available

What is your approach to the decision to use CPX-351 or standard 7+3 for de novo AML?

Do you await molecular and cytogenetic results prior to initiating therapy, or does age and function status primarily drive your choice?

2 Answers available

What is your preferred TKI and dosing for AYAs or adult patients with Ph+ ALL?

NCCN does not list any preferences for the TKIs in their guidelines.

1 Answer available

What is the role (if any) for Rituximab in a patient with CD20+, Philadelphia chromosome positive ALL?

1 Answer available

Would using Obinutuzumab and Venetoclax second line after Bendamutine and Rituximab be a reasonable option for a patient with IGHV-unmutated CLL?

1 Answer available

How do you dose midostaurin in patients with AML who need azole antifungal prophylaxis?

FDA package insert lists posaconazole as strong cyp3A4 inhibitor and states to consider other therapies.

1 Answer available

How much later after starting a hypomethylating agent in an elderly patient with AML being treated in the upfront setting can venetoclax be started?

Can it be added after 2 or 3 cycles of HMA?

1 Answer available

Do you make diagnostic lumbar puncture part of routine work up for newly diagnosed AML if patient is asymptomatic?

Does presenting total white blood cell count affect your decision? Does myeloid subtype affect your decision?

1 Answer available

Why are hypomethylating agents as single agents not approved yet by FDA for treatment of AML (technically off-label)?

2 Answers available

How would you approach treatment in an older (>65), but fit patient with intermediate-risk AML, but with MRD persistence after induction with 7+3?

How might your decision change if the patient had a suitable 10/10 donor? How about if the patient had a targetable molecular mutation such as IDH2?

1 Answer available

In a patient with high risk acute promyelocytic leukemia, when do you consider ATRA+ATO with GO vs ATRA+ATO with idarubicin?

1 Answer available

Will you offer Ibrutinib and Rituximab for untreated patients with CLL without a 17p deletion?

Shanafelt et al. recently presented results from the phase III E1912 study at ASH 2018. Will you still utilize FCR as first-line or now use Ritux...

1 Answer available

What is your approach to choosing a conditioning regimen for allogeneic transplant in AML?

What factors influence your decision (patient/disease characteristics, additional agents added to induction chemotherapy, CR1 or later, etc)?

1 Answer available

How do you approach the treatment of hairy cell leukemia with inadequate response to front line therapy?

If a patient obtains a PR or less to front line cladribine, what factors help you chose between a second course of cladribine, an alternative pur...

1 Answer available

What is your general approach to post-allogeneic HSCT maintenance therapy for AML?

When is it warranted to utilize targeted therapies for known mutations (eg. midostaurin or an alternative TKI for FLT3 mutations, ivosidenib for ...

2 Answers available

Would you use alternative management in a chronic phase CML with a 3 way translocation between chromosome 9, 22 and 7?

1 Answer available

Does anything need to be done if hyperlymphocytosis (i.e. ALC > 300K) develops in a CLL patient just starting ibrutinib?

1 Answer available

If you decide to discontinue TKI after prolonged molecular remission in CML, how often would you follow the BCR/ABL after discontinuation?

1 Answer available

What is your experience with liposomal-encapsulated daunorubicin and cytarabine (CPX-351) for first line treatment of therapy-related AML or AML with myelodysplasia-related changes in elderly patients?

Do you have experience administering these agents in the outpatient setting?

2 Answers available

Is there a situation where you would use a purine analogue in combination with rituximab for the frontline line treatment of normal variant Hairy Cell Leukemia?

Could one make a case for addition of Rituxinab frontline to increase the chances of a complete remission and even maybe achieve MRD-negative status ?

1 Answer available

What is the best strategy after initial treatment with hypomethylating agents for high grade myelodysplatic syndromes, mainly for responders who became transfusion independent?

Do we continue the hypomethylating agent indefinitely?

1 Answer available

Do you routinely do imaging on patients to look for intrathoracic or abdominal lymphadenopathy in newly diagnosed patients with CLL?

1 Answer available

How are you making the diagnosis of chronic lymphocytic leukemia transforming to prolymphocytic leukemia?

Technically, you can have up to 55% of larger cells circulating and still be called CLL.

1 Answer available

Do you give 3 or 4 cycles of HiDAC during consolidation for good/intermediate-risk AML without an available allotransplant donor?

How do you choose between 3 and 4?

1 Answer available

How do you approach small lymphocytic lymphoma that does not have a leukemic phase?

Do you follow treatment guidelines for indolent lymphoma or CLL? How do you get 17p testing on someone with only lymphadenopathy?

1 Answer available

Do you think there will be a role for duvelisib in the treatment of relapsed/refractory chronic lymphocytic leukemia?

Specifically, in patients that had progression or developed toxicity on ibrutinib? Idelalisib is very toxic and venetoclax a labor-intensive drug to g...

1 Answer available

When do you combine hypomethylating agents with venetoclax or gemtuzumab ozogamicin in elderly patients with AML who are ineligible for intensive chemotherapy?

Even though Venetoclax is not FDA-approved yet, assuming you can get it off label? 1. Gemtuzumab: What dose/schedule and which HMA? 2. Venetoclax: W...

1 Answer available

Would you consider aggressive presentation of multiple squamous cell carcinomas of the skin an indication for treatment of CLL?

In the absence of any other classic CLL indications for treatment.

1 Answer available

What would you choose as a first line therapy for a patient with CLL who is asymptomatic with Rai Stage 4 with bulky adenopathy and organomegaly?

Would it change your management if patient if IgVH mutated?

1 Answer available

What is your preferred dosing and schedule for interferon in pregnant CML patients?

1 Answer available

Is venetoclax expected to be useful in patients with refractory CLL/SLL who do not have Del(17p)?

1 Answer available

For male patients in chronic phase CML on a TKI and not yet in a MMR, is there a preferred amount of time spent in a MMR before discontinuing TKI therapy to conceive or bank sperm ?

Drug information indicates a patient may need 3-4 months off TKI. This seems like a long time off drug. Would a MMR of a certain duration make it less...

1 Answer available

How would you approach a chronic phase CML patient who is responding to second generation TKI but not yet in molecular remission and is now pregnant?

2 Answers available

How do you manage a patient who has developed a symptomatic pleural effusion while on dasatinib?

Specifically, can you rechallenge after the effusion has resolved (e.g. therapeutic thoracentesis)? If so, how long do you wait to rechallenge (especi...

2 Answers available

When starting a patient on a tyrosine kinase inhibitor for chronic phase CML, which drug do you choose upfront?

Imatinib, or a second-generation TKI? Are there specific factors that make you choose one over the other?

2 Answers available

After induction therapy for acute promyelocytic leukemia with arsenic trioxide and ATRA, at what point do you start consolidation?

Specifically, do you just wait for count recovery? Do you check for morphologic or molecular remission at all during this time?

1 Answer available

How would you treat a young man with refractory AML after HIDAC induction who developed cerebellar toxicity to HIDAC and previously received doxorubicin (300 mg/m2) for lymphoma?

What re-induction regimen without cytarabine or an anthracycline is likely to be most effective?

1 Answer available

Should FISH studies be repeated when CLL patients under active surveillance have progressive disease warranting treatment?

What is the utility of repeating FISH studies to evaluate for clonal evolution if FISH studies were done at diagnosis?

1 Answer available

When would you consider testicular RT prior to TBI for BMT?

What dose do you recommend?

1 Answer available

Papers discussed in this category

Cancer, 2004-08-15

The incidence of testicular recurrence in boys with acute leukemia treated with total body and testicular irradiation and stem cell transplantation.

Br. J. Haematol., 2003-11-01

Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia.

Br. J. Haematol., 1998-08-01

Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Société Française de Greffe de Moelle study.

Cancer, 1990-11-15

Testicular relapse in children with acute nonlymphoblastic leukemia.

Radiother Oncol, 1990-01-01

Total body irradiation for bone marrow transplantation: the Memorial Sloan-Kettering Cancer Center experience.

The New England journal of medicine, 2010-06-17

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Blood, 2014-01-23

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

The New England journal of medicine, 2010-06-17

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

The New England journal of medicine, 2015-12-17

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Blood, 2022 Jul 14

Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.

Leukemia, 2021 Apr 27

Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.

J Am Coll Cardiol, 2019 Oct 01

Cardiovascular Toxicities Associated With Ibrutinib.

Medical and pediatric oncology, 1981

The cytosine arabinoside (Ara-C) syndrome.

Blood, 2014 Feb 05

Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.

British journal of haematology, 2004-04

Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.

Blood,

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

Blood,

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.

Br. J. Haematol., 2017 Nov 21

The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.

Blood, 2018-06-21

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Nature, 2019-06

Growth dynamics in naturally progressing chronic lymphocytic leukaemia.

Leukemia, 2019-02

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.

The Lancet. Oncology, 2009-03

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-05-15

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Cancer, 2011-06-15

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

American journal of hematology, 2009-09

A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.

Cancer, 2010-08-15

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.

Blood, 2013-11-14

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.

J. Clin. Oncol., 2016 Jan 25

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.

Leukemia, 2016-02

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.

The Lancet. Oncology, 2018-02

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.

Avicenna J Med, 2017 Jul-Sep

An unusual presentation of chronic lymphocytic leukemia.

Blood, 2014-05-22

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-10

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

Fertil. Steril., 2013 Sep 05

Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion.

Leukemia, 2018-08

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

The New England journal of medicine, 2015-10-29

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

Blood, 2017-03-09

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

Cancer, 2015-12-01

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-08-01

Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.

The New England journal of medicine, 2017-08-03

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

Lancet, 2012 Apr 05

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Haematologica, 2018 Aug 03

Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.

Cancer, 2014-12-01

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

Blood, 1998-09-01

A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.

Blood, 2019-04-04

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

Cell stem cell, 2017-09-07

Blood,

The World Health Organization (WHO) classification of the myeloid neoplasms.

Blood, 2019-01-03

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Leukemia, 2019 Oct 18

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.

American journal of hematology, 2018-08

Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.

Am. J. Hematol., 2019 Nov 19

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.

N. Engl. J. Med.,

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-04-01

Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-04-01

Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group.

Nature medicine, 2015-02

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.

Clin Lymphoma Myeloma Leuk, 2017 Jun 21

Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.

The New England journal of medicine, 2007-01-25

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Blood, 2016-07-28

Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Blood advances, 2016-12-27

US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.

Cancer, 2016-10

Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Blood, 2017-08-31

Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia.

Biol. Blood Marrow Transplant., 2019 Aug 22

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.

Blood, 2018-07-19

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia.

, 2019 Oct 29

Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force.

, 2018 Feb 27

Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis.

N Engl J Med, 2019 Oct 31

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

Blood,

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Blood, 2018 Apr 5

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.

N Engl J Med,

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.

The New England journal of medicine, 2018-03-22

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Lancet Oncol, 2016 May 20

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.

Lancet Oncol,

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.

Clin Lymphoma Myeloma Leuk, 2017 Mar 07

Myeloid Sarcoma: Presentation, Diagnosis, and Treatment.

Lancet Oncol, 2020 Mar 11

Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.

British journal of haematology, 2011-11

Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial.

Haematologica, 2020 Feb 6

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group.

Leuk Lymphoma, 2019 Nov 04

Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.

J Clin Oncol, 2021 Jul 26

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-02-20

High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.

Lancet (London, England), 2010-12-11

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.

Blood, 2012 Apr 04

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.

Clin Lymphoma Myeloma Leuk, 2019 Sep 30

Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.

Bone Marrow Transplant, 2018 Jun 08

Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?

The Lancet. Oncology, 2017-09

Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.

J Clin Oncol, 2020 Apr 10

Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.

Haematologica, 2015-01

Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective.

Blood advances, 2019-01-22

Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib.

Am J Hematol, 2019 Apr 04

Low-dose vemurafenib in hairy cell leukemia patients with active infection.

N Engl J Med,

Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.

Clin Infect Dis,

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Blood, 2008-02-15

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).

The Lancet. Haematology, 2018-12

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.

Pharmacogenomics,

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.

Pediatr Blood Cancer, 2011 Feb 22

A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia.

Pediatr Blood Cancer, 2011 Jul 27

Pharmacogenetics, cost of genotyping, and guidelines for individualizing therapy with mercaptopurine in pediatric acute lymphoblastic leukemia.

Int J Hematol, 2021 Oct 28

NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China.

Pharmacogenet Genomics,

Cost-effectiveness analysis of pretreatment screening for NUDT15 defective alleles.

American journal of hematology, 2020 Dec 08

Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.

Blood cancer journal, 2023 Oct 11

Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia.

BMC Cancer, 2010 Aug 09

In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells.

Journal of hospital medicine, 2018-08-01

Things We Do For No Reason: Neutropenic Diet.

Front Oncol, 2022 Mar 09

Neutropenic Diet Cannot Reduce the Risk of Infection and Mortality in Oncology Patients With Neutropenia.

BMJ Support Palliat Care, 2022 Jul 08

Neutropenic versus regular diet for acute leukaemia induction chemotherapy: randomised controlled trial.

Nutr Cancer, 2019 Oct 12

Lack of Efficacy of the Neutropenic Diet in Decreasing Infections among Cancer Patients: A Systematic Review.

The Lancet. Oncology, 2018-01

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-01

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Blood,

Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.

Oncotarget,

T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.

Haematologica, 2022 Apr 01

Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.

Blood, 2012 Oct 31

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).

Clin Lymphoma Myeloma Leuk, 2020 Jul 29

Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis.

Blood, 2006-05-01

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-02-01

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

The Lancet. Oncology, 2015-10

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.

N Engl J Med, 2013 Jul 11

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Blood, 2012 Jun 19

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).

Blood, 2017-09-28

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.

Blood, 2019-04-11

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

Blood Adv, 2022 Jun 14

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.

J Clin Oncol, 2021 Oct 07

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.

J Clin Pharmacol, 2021 Jul 16

Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-11-01

Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.

Blood Adv, 2021 Aug 24

Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.

Blood, 2014 Apr 16

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.

J Clin Oncol, 2018 Mar 02

IKZF1 Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.

N Engl J Med, 2009 Jan 07

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

Hered Cancer Clin Pract, 2021 Apr 01

Should the BCRA1/2-mutations healthy carriers be valid candidates for hematopoietic stem cell donation?

Leukemia, 2014-03

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.

Lancet Oncol, 2021 Nov 11

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.

Blood, 2022 Oct 20

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.

N Engl J Med, 2023 Jun 05

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

N Engl J Med, 2023 Jun 05

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

JAMA, 2021 Mar 02

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

American journal of hematology, 2024 Feb 05

Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.

Pediatric blood & cancer, 2015-06

Clinical application of asparaginase activity levels following treatment with pegaspargase.

Leukemia & lymphoma, 2018-08

Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.

Haematologica, 2016 Mar

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.

Bone marrow transplantation, 2020 Dec 07

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 Jul 16

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN).

Leukemia & lymphoma, 2020 Aug 24

Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Gut, 2019 Sep 27

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Expert opinion on drug safety, 2017 Mar 29

Effect of methotrexate on bone and wound healing.

The Lancet. Haematology, 2023 May 12

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Oct 26

Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.

Cancer, 2016-12-01

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.

The Lancet. Oncology, 2015-11

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-02

High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.

Journal of oncology practice, 2018-09-04

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update Summary.

Leukemia & lymphoma, 2022 Mar 15

Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.

Hematology. American Society of Hematology. Education Program, 2020 Dec 04

Updates in infection risk and management in acute leukemia.

Blood advances, 2023 Aug 22

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.

Archives of drug information, 2008-12

A Phase 3, Randomized, Placebo-controlled Trial of Filgrastim in Patients with Haematological Malignancies Undergoing Matched-related Allogeneic Bone Marrow Transplantation.

Bone marrow transplantation, 2003 Jul

G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003 Dec 22

Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Leukemia, 2005 Apr

Graft-versus-host-disease and granulocyte colony-stimulating factor administration after allogeneic stem cell transplantation.

Transplantation and cellular therapy, 2021 Oct 02

Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy.

Lancet (London, England), 2020 Apr 18

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.

The Lancet. Oncology, 2023 May

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

The New England journal of medicine, 2023 Dec 10

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Medicina oral, patologia oral y cirugia bucal, 2008 Oct 01

Malignant mental nerve neuropathy: systematic review.

Blood, 2023 Mar 23

How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Jun 13

Blinatumomab Conundrum in Low-Risk Relapsed B-Cell ALL.

Br J Haematol, 2023 Dec 10

Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.

Blood advances, 2024 Jan 09

Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.

Blood advances, 2023 Apr 11

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2024 Jan 05

PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.

Leukemia

Questions discussed in this category

Papers discussed in this category

Related Topics